Sentence examples for cgp i from inspiring English sources

CGP: I actually started the company myself in 2009 and recently added two other company members.

We have previously shown that 100 nM BODIPY-TMR-CGP binds to the secondary low affinity conformation of the β1-adrenoceptor, and as such may cause allosteric effects that result in an enhanced dissociation rate of 100 nM BODIPY-TMR-CGP (i.e., negative cooperativity) from the primary high-affinity β1-adrenoceptor conformation.

The guidelines provided conformed to HC recommendations and CGP guidelines (i.e., according to HC recommendations in Table  1 but only in the tetanus prone cases) in 11 (21%) and 27 (52%) cases, respectively.

Similarly, the HT-estimator of Eq. (2) is exploited from (4) PGP it * = β 1 PSP it * + β 2 CSP it * + β 3 CGP it * + X i * γ + μ i * + ɛ it *, using z ¯ it, z ¯ ¯ it = z it − z ¯ it and the level of the time-invariant but exogenous X i -variables as instruments, where z ∈ { PSP, CSP, CGP}.

10 Denoting the GLS transform of each variable with '*', we finally obtain the HT-estimator from the regressions (3) PSP it * = α 1 PGP it * + α 2 CSP it * + α 3 CGP it * + X i * δ + λ i * + ν it *, using the within average y ¯ it, y ¯ ¯ it = y it − y ¯ it and the level of the time-invariant but exogenous X i -variables as instruments, where y ∈ { PGP, CSP, CGP}.

As a consequence we examined the competition binding curves of CGP 20712A, propranolol and CGP 12177 using BODIPY-TMR-CGP concentrations up to 100 nM.

Given that it is possible for a β1-selective compound to be devoid of β2 effects (i.e., CGP 20712A), there is clearly a need for the development of β-blockers with improved selectivity for clinical use.

Within this analysis, koff(fast) and Plateau was constrained to the average rate of dissociation and the average Plateau (in %) reached by BODIPY-TMR-CGP in control CHO-CS cells (i.e., cell not expressing the receptor of interest to determine the nonspecific BODIPY-TMR-CGP binding component).

Association kinetic data were fitted using the following monoexponential association equation: where Y 0 is the level of BODIPY-TMR-CGP binding at time t = 0 (i.e., baseline fluorescence), Plateau is the level of BODIPY-TMR-CGP binding at infinite time, and konobs is the rate of observed association.

This tendency respectively inhibits positron trapping in β-CGP, as it follows from over 30%% reduction in I 2 intensity, and nearly the same increase in defect-related τ 2 lifetime.

cGP models thus allow the construction of genotype-phenotype maps, i.e. mappings predicting the phenotype associated with a given genotype based on what we know about the regulatory anatomy of a given biological system.